STOCK TITAN

Lilly(Eli) & Co - LLY STOCK NEWS

Welcome to our dedicated news page for Lilly(Eli) & Co (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly(Eli) & Co.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lilly(Eli) & Co's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lilly(Eli) & Co's position in the market.

Rhea-AI Summary
Eli Lilly and Company announces positive results from a Phase 3 study of lebrikizumab for people with skin of color and moderate-to-severe atopic dermatitis. The study shows improvement in skin clearance and itch relief, with significant efficacy in patients of various skin tones. Lebrikizumab demonstrates potential as a first-line biologic treatment, addressing the unmet needs of underserved populations. The study includes diverse patient groups, with 68% experiencing a 75% improvement in disease severity, 46% achieving a 90% improvement, and 39% attaining clear or almost clear skin. The results are presented at the American Academy of Dermatology Annual Meeting, highlighting Lilly's commitment to health equity in dermatology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.64%
Tags
none
-
Rhea-AI Summary
Eli Lilly and Company announces FDA advisory committee meeting to discuss Phase 3 trial of donanemab for Alzheimer's disease, delaying expected FDA action in 2024. The trial shows promising results but raises safety concerns.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
none
-
Rhea-AI Summary
Eli Lilly and Company launches new films as part of its Get Better campaign, focusing on obesity and the appropriate use of anti-obesity medications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.05%
Tags
none
Rhea-AI Summary
Eli Lilly and Company announces preclinical data for agents targeting Nectin-4, KRAS G12D, and BRM (SMARCA2) to be presented at AACR Annual Meeting. New data includes a monoclonal anti-Nectin-4 antibody, a KRAS G12D inhibitor, and a BRM (SMARCA2) inhibitor. IND applications planned for all three programs in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
none
-
Rhea-AI Summary
Eli Lilly and Company (LLY) will participate in Cowen's 44th Annual Health Care Conference on March 6, 2024. Anat Ashkenazi, CFO, will engage in a fireside chat at 9:10 a.m. ET. The event will be live webcasted on Lilly's Investor website, with a replay available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.38%
Tags
conferences
-
Rhea-AI Summary
Eli Lilly and Company (NYSE:LLY) announces the retirement of Philip Johnson, group vice president and treasurer, after 28 years of service. Johnson's impactful leadership in finance, business operations, and investor relations is highlighted, with his successor to be named later.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
none
Rhea-AI Summary
Eli Lilly and Company (LLY) announced a 28% increase in revenue in Q4 2023, with a significant growth in New Products and Growth Products revenue. The company also achieved pipeline progress, FDA approvals, and completed acquisitions, issuing a 2024 guidance of $40.4 billion to $41.6 billion in revenue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
-
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) announced the retirement of Johna Norton, executive vice president of Global Quality, after 34 years of service. An internal and external search is underway for her successor. Norton has made significant contributions to the company's quality standards, manufacturing processes, and team development. She has been instrumental in the successful transition of new molecules from development to manufacturing and the implementation of continuous manufacturing processes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
-
Rhea-AI Summary
Akouos, Inc., a subsidiary of Eli Lilly and Company, announced positive initial clinical results from the Phase 1/2 AK-OTOF-101 study, demonstrating hearing restoration within 30 days of AK-OTOF administration in the first participant with profound hearing loss. The study focuses on AK-OTOF gene therapy for OTOF-mediated hearing loss due to mutations in the otoferlin gene. The results will be presented at the 2024 Association for Research in Otolaryngology MidWinter Meeting. The initial participant, an 11-year-old with profound hearing loss from birth, experienced restored hearing across all tested frequencies, achieving thresholds within the normal hearing range at some frequencies. The therapy was well tolerated with no serious adverse events reported. AK-OTOF has been granted Orphan Drug Designation and Rare Pediatric Disease Designation by the FDA and has received a positive opinion on orphan drug designation by the EMA Committee for Orphan Medicinal Products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) is set to announce its fourth-quarter 2023 financial results and 2024 financial guidance on Feb. 6, 2024. The company will conduct a conference call to provide detailed information to the investment community and media. The conference call will be accessible through a live webcast on Lilly's website, with a replay available afterward.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
Lilly(Eli) & Co

NYSE:LLY

LLY Rankings

LLY Stock Data

722.19B
897.86M
0.16%
84.31%
0.57%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Indianapolis

About LLY

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War.